

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 September 2024 (19.09.2024)



(10) International Publication Number
WO 2024/192308 A2

- (51) **International Patent Classification:**
Not classified
- (21) **International Application Number:**
PCT/US2024/020035
- (22) **International Filing Date:**
14 March 2024 (14.03.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|-----------------------------|----|
| 63/490,167 | 14 March 2023 (14.03.2023) | US |
| 63/490,171 | 14 March 2023 (14.03.2023) | US |
| 63/495,989 | 13 April 2023 (13.04.2023) | US |
| 63/496,374 | 14 April 2023 (14.04.2023) | US |
| 63/578,592 | 24 August 2023 (24.08.2023) | US |
- (71) **Applicant: XENCOR, INC.** [US/US]: 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US).

- (72) **Inventors: MOORE, Gregory;** C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). **DAVRA, Viralkumar, Rameshkumar;** C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). **NAM, Dong, Hyun;** C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). **GUSTI ZENG, Veronica;** C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). **HEDVAT, Michael;** C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). **QI, Jing;** C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). **RASHID, Rumana;** C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). **ARPP, Patrick;** C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). **DELGADO, Ernesto;** C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). **TAN, Chaofang;** C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). **BAKHIT, Charles, G.;** C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). **DIAZ, Juan;** C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). **PRECIADO JIMENEZ, Heather;** C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US).

- (74) **Agent: NGUYEN, Louis-vu, T. et al.;** Morgan, Lewis & Bockius, LLP, One Market, Spear Street Tower, San Francisco, CA 94105 (US).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

- (54) **Title:** ANTI-CD28 COMPOSITIONS

- (57) **Abstract:** Provided herein are novel anti-CD28 x anti-STEAP1 and anti-CD28 x anti-CEACAM5 antibodies and methods of using such antibodies for the treatment of related cancers.



WO 2024/192308 A2